+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tumor Drug"

Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2024 - Product Thumbnail Image

Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Tenosynovial Giant Cell Tumors - Pipeline Insight, 2024 - Product Thumbnail Image

Tenosynovial Giant Cell Tumors - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
From
From
From
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
From
From
From
Anti-Tumor Drugs Industry Forecasts - China Focus - Product Thumbnail Image

Anti-Tumor Drugs Industry Forecasts - China Focus

  • Report
  • November 2023
  • 107 Pages
  • China
From
From
Loading Indicator

The Tumor Drug market is a subset of the Oncology Drugs market, which focuses on the development and sale of drugs used to treat cancer. These drugs are used to target and destroy cancer cells, reduce the size of tumors, and reduce the spread of cancer. Tumor drugs are typically divided into two categories: cytotoxic drugs, which kill cancer cells, and targeted therapies, which target specific molecules involved in cancer growth. These drugs are often used in combination with other treatments, such as radiation and surgery, to maximize the effectiveness of treatment. The Tumor Drug market is highly competitive, with many companies developing and selling drugs to treat cancer. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, Novartis, and Roche. Other companies, such as AstraZeneca, Eli Lilly, and Amgen, are also active in the market. Show Less Read more